MedTrace Logo

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

NCT04302025 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2026-05-22

No results posted yet for this study

Summary

This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

Conditions

Interventions

DRUG

Alectinib

Participants will receive oral alectinib twice per day (BID).

DRUG

Entrectinib

Participants will receive oral entrectinib daily.

DRUG

Vemurafenib

Participants will receive oral vemurafenib BID.

DRUG

Cobimetinib

Participants will receive oral cobimetinib daily.

DRUG

Pralsetinib

Participants will receive oral pralsetinib daily.

DRUG

Atezolizumab

Atezolizumab will be administered by intravenous (IV) infusion.

DRUG

SBRT

Participants will receive SBRT given concurrently, starting with the first dose of atezolizumab.

PROCEDURE

Resection

Participants will receive surgical resection of the primary tumor along with selected lymph nodes per SOC.

DRUG

Chemotherapy

Participants will receive SOC chemotherapy as determined by the treating physician.

DRUG

Divarasib

Participants in the KRAS G12C cohort will receive oral divarasib for approximately 8 weeks until the day before surgery as neoadjuvant therapy up to 3 years as adjuvant therapy.

Sponsors & Collaborators

  • Genentech, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-06
Primary Completion
2026-11-30
Completion
2030-05-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04302025 on ClinicalTrials.gov